Search Results - "Akagündüz, Baran"

Dynamic changes in systemic immune‐inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy by Demircan, Nazım Can, Atcı, Muhammed Mustafa, Demir, Metin, Işık, Selver, Akagündüz, Baran

“…Aim Systemic inflammation has been associated with chemoresistance and prognosis in solid tumors. Systemic immune‐inflammation index (SII) is a novel marker…”
Get full text

Malnutrition and Related Factors in Older Patients With Gastrointestinal Cancer Receiving Chemotherapy by Doğan Akagündüz, Diğdem, Şahin, Hilal, Akagündüz, Baran

“…Objectives The incidence and mortality of gastrointestinal (GI) malignancies increase exponentially with age. Malnutrition is a documented poor prognostic…”
Get full text

Association of Serum Hepatocyte Growth Factor Level with Systemic Inflammatory Biomarkers in Patients with Pancreatobiliary Cancer by Ünek, İlkay Tuğba, Öztop, İlhan, Başbınar, Yasemin, Ünek, Tarkan, Leblebici, Asım, Çakıroğlu, Ece, Uysal, Tuğba, Akagündüz, Baran, Ellidokuz, Hülya, Astarcıoğlu, İbrahim

“…Hepatocyte growth factor is a cytokine secreted by the stromal cells in the tumor microenvironment. There is little information about the clinical significance…”
Get full text

Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer by Akagündüz, Baran, Guven, Deniz Can, Ozer, Muhammet, Okten, Ilker Nihat, Atag, Elif, Unek, İlkay Tugba, Tatli, Ali Murat, Karaoglu, Aziz

Get full text

Geriatric nutritional risk index and controller nutritional status score before metastatic first-line chemotherapy predict survival in patients over 70 years of age with metastatic bladder cancer by Balçık, Onur Yazdan, Demir, Bilgin, Ilhan, Yusuf, Akagündüz, Baran

“…Several prognostic factors have been identified in patients with metastatic bladder cancer (BC). As it is known, older adult patients are prone to nutritional…”
Get full text

Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer by Taşçı, Elif Şenocak, Oyan, Başak, Sönmez, Özlem, Mutlu, Arda Ulaş, Atcı, Muhammed Mustafa, Sakin, Abdullah, Öner, İrem, Çınkır, Havva Yeşil, Eryılmaz, Melek Karakurt, Çağlayan, Dilek, Balçık, Onur Yazdan, Paksoy, Nail, Karabulut, Senem, Salim, Derya Kıvrak, Bilir, Cemil, Özen, Miraç, Özçelik, Melike, Arıcan, Ali, Akagündüz, Baran, İnal, Ali, Aydın, Dinçer, Özer, Leyla, Gülmez, Ahmet, Turhal, Nazım Serdar, Esen, Selin Aktürk, Algın, Efnan, Akbaş, Sinem, İriağaç, Yakup, Şakalar, Teoman, Ünal, Çağlar, Er, Özlem, Seçmeler, Şaban, Bozkurt, Mustafa

Get full text

The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy by Sakin, Abdullah, Atci, Muhammed M, Aldemir, Mehmet Naci, Akagündüz, Baran, Şahin, Suleyman, Arıcı, Serdar, Secmeler, Saban, Cihan, Sener

“…Objective In this study, we aimed to investigate the prognostic value of postoperative lymph node ratio (LNR)in locally advanced gastric cancer (GC) patients…”
Get full text

Assessment of Prognostic Factors and Adjuvant Treatment Modalities in Adult Head and Neck Soft Tissue Sarcoma Patients Treated With Upfront Surgery by Akagündüz, Baran, Akin Telli, Tugba, Sezgin Goksu, Sema, Yildirim, Hasan Cagri, Ozer, Muhammet, Göktaş Aydin, Sabin, Ozyurt, Neslihan, Karacin, Cengiz, Paydas, Semra, Dogan, Mutlu

“…Objectives Head and neck soft tissue sarcomas (HNSTSs) are a heterogeneous group of rare tumors. Surgical resection with negative margins remains the standard…”
Get full text

Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials by Ozer, Muhammet, Goksu, Suleyman Yasin, Akagunduz, Baran, George, Andrew, Sahin, Ilyas

“…Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Immune checkpoint inhibitors (ICIs) have become the new reference standard in…”
Get full text

Protective effects of taxifolin on pazopanib-induced liver toxicity: an experimental rat model by Akagunduz, Baran, Ozer, Muhammet, Ozcıcek, Fatih, Kara, Ali Veysel, Lacın, Sahin, Özkaraca, Mustafa, Çoban, Abdulkadir, Suleyman, Bahadır, Mammadov, Renad, Suleyman, Halis

“…Pazopanib is a tyrosine kinase inhibitor that is generally used for the treatment of metastatic renal cell cancer and advanced soft tissue sarcoma. It can…”
Get full text

Tuberculous Lymphadenitis in a Patient Receiving PD-1 Inhibitor for Melanoma: A Case Report and Brief Literature Review by Akagunduz, Baran, Ozer, Muhammet, Bozkina, Ali Cagatay, Lebe, Banu

“…Oncolytic immunotherapy is a novel and promising approach in clinical oncology practice. Currently, immune checkpoint inhibitors (ICIs) are the first-line…”
Get full text

Assessment of abuse and related factors in older patients with cancer by Akagunduz, Baran, Altın, Zeynep, Atcı, Muhammed Mustafa, Ozer, Muhammet, Güven, Deniz Can, Çil, İbrahim, Özçiçek, Fatih, Demirtaş, Levent, Duzgun, Eren, Gunderci, Azad, Arslan, Yusuf

“…Background Older cancer patients are more likely to present with functional dependency, multiple comorbidities, polypharmacy, malnutrition, and cognitive…”
Get full text

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study) by Hizal, Mutlu, Bilgin, Burak, Paksoy, Nail, Atcı, Muhammed Mustafa, Kahraman, Seda, Kılıçkap, Saadettin, Güven, Deniz Can, Keskinkılıç, Merve, Ayhan, Murat, Eren, Önder, Mustafayev, Fatma Nihan Akkoç, Yaman, Şebnem, Bayram, Ertuğrul, Ertürk, İsmail, Özcan, Erkan, Korkmaz, Mustafa, Akagündüz, Baran, Erdem, Dilek, Telli, Tuğba Akın, Aksoy, Asude, Üskent, Necdet, Baytemür, Naziyet Köse, Gülmez, Ahmet, Aydın, Dinçer, Şakalar, Teoman, Arak, Hacı, Tatlı, Ali Murat, Ergün, Yakup, Ak, Naziye, Ünal, Çağlar, Özgün, Mehmet Alpaslan, Yalçın, Bülent, Öztop, İlhan, Algın, Efnan, Sakin, Abdullah, Aydıner, Adnan, Yumuk, Perran Fulden, Şendur, Mehmet Ali Nahit

“…Introduction Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced…”
Get full text

Efficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systemic review and meta-analysis by Ergun, Yakup, Ucar, Gokhan, Akagündüz, Baran

“…The rate of pathological complete response (pCR) with both chemotherapy alone (CT) and endocrine therapy (ET) in the neoadjuvant (Na) treatment of hormone…”
Get more information

The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study by Kus, Fatih, Can Guven, Deniz, Yildirim, Hasan Cagri, Akagunduz, Baran, Karakaya, Serdar, Sutcuoglu, Osman, Chalabiyev, Elvin, Akyildiz, Arif, Koksal, Baris, Sahin, Yigit Berk, Karaca, Ece, Kavruk, Oguz Alp, Zor, Nefise Tugce, Sirvan, Firat, Yazici, Ozan, Yalcin, Suayib

“…This study aimed to assess the habits and knowledge of cancer patients regarding the use of herbal medicines and dietary supplements in cancer patients…”
Get full text

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer by Esen, Selin Akturk, Ergun, Yakup, Erol, Cihan, Arikan, Rukiye, Er, Muhammed Muhiddin, Atci, Muhammed Mustafa, Topcu, Atakan, Ucar, Gokhan, Akagunduz, Baran, Aykan, Musa Baris, Ozen, Mirac, Baytemur, Naziyet Kose, Ozcelik, Melike, Sahin, Elif, Guven, Denizcan, Menekse, Serkan, Ak, Naziye, Teker, Fatih, Kut, Engin, Sakalar, Teoman, Alan, Ozkan, Kacan, Turgut, Turhal, Nazim Serdar, Kilickap, Saadettin, Turker, Sema, Sendur, Mehmet Ali Nahit, Kostek, Osman, Karaagac, Mustafa, Sakin, Abdullah, Turk, Haci Mehmet, Caglayan, Dilek, Cihan, Sener, Acikgoz, Yusuf, Uncu, Dogan

“…Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of human epidermal growth factor receptor 2…”
Get full text

Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study by Hizal, Mutlu, Bilgin, Burak, Paksoy, Nail, Kılıçkap, Saadettin, Atcı, Muhammed Mustafa, Kahraman, Seda, Keskinkılıç, Merve, Bilgetekin, İrem, Ayhan, Murat, Tural, Deniz, Eren, Önder, Akkoç Mustafayev, Fatma Nihan, Yaman, Şebnem, Tatlı, Ali Murat, Bayram, Ertuğrul, Kutlu, Yasin, Ertürk, İsmail, Özcan, Erkan, Gülmez, Ahmet, Korkmaz, Mustafa, Akagündüz, Baran, Erdem, Dilek, Telli, Tuğba Akın, Aksoy, Asude, Üskent, Necdet, İriağaç, Yakup, Baytemür, Naziyet Köse, Aydın, Dinçer, Şakalar, Teoman, Arak, Hacı, Selçukbiricik, Fatih, Ergün, Yakup, Korkmaz, Taner, Ak, Naziye, Ünal, Çağlar, Akdeniz, Nadiye, Özgün, Mehmet Alpaslan, Öksüzoğlu, Berna, Yalçın, Bülent, Öztop, İlhan, Algın, Efnan, Sakin, Abdullah, Aydıner, Adnan, Yumuk, Perran Fulden, Şendur, Mehmet Ali Nahit

“…In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. This retrospective trial included…”
Get full text

By 2022, Cancer is Now a More Chronic Disease with Chronic Difficulties to Go Along with It by SÜMBÜL, Ahmet Taner, SEDEF, Ali Murat, KARAÇİN, Cengiz, BİLİR, Cemil, AKAGÜNDÜZ, Baran

Get full text

Determining the Current Situation of Geriatric Oncology in Turkey: A Survey of Medical Oncologists by AKAGÜNDÜZ, Baran, GÜVEN, Deniz Can, ATCI, Muhammed Mustafa, ÇİL, İbrahim, KARAÇİN, Cengiz, ÖZER, Muhammet, KILIÇKAP, Saadettin

Get full text

Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis by Ergun, Yakup, Ucar, Gokhan, Akagunduz, Baran

“…•The biological distinctness of HER2-low and its prognostic significance remain unclear.•Our study analyzed 23 studies involving 636,535 patients, comparing…”
Get full text